Autres langues CStone Pharmaceuticals Deutsche Boerse AG

Actions

PH4

KYG2588M1006

Produits pharmaceutiques

Marché Fermé - Deutsche Boerse AG 15:25:01 02/10/2026			Varia. 5j.	Varia. 1 janv.
0,6216 ^EUR	-2,63%		+7,54%	+9,05%

24/09	Le directeur général de CStone Pharma achète pour 2,7 millions de dollars de Hong Kong d’actions	MT
07/09	CStone Pharmaceuticals intègre le Stock Connect pour le trading Southbound	MT

Autres langues

24/09	CStone Pharma CEO Buys HK$2.7 Million of Shares
07/09	CStone Pharmaceuticals Joins Stock Connect Southbound Trading
31/08	CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
31/08	CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
31/08	Cstone Pharmaceuticals Provides Updates on Cs2009 and Pipeline 2.0 Clinical Trials and Product Portfolio
27/08	CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
27/08	CStone Pharmaceuticals Reports Earnings Results for the Half Year Ended June 30, 2026
21/08	CStone Pharmaceuticals' Application for Tumor Drug Gets China Nod in 23 Days
20/07	Cstone Pharmaceuticals Announces Updated Clinical Data and Esmo 2026 Presentations for Cs2009 Trispecific Antibody
29/06	MÄRKTE ASIEN/Positive Vorzeichen überwiegen - Anleger setzen auf Ende des Iran-Kriegs
29/06	MÄRKTE ASIEN/Uneinheitlich - Pharmawerte in China haussieren
26/06	CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
26/06	CStone Pharma Taps Arrotex to Commercialize Sugemalimab in Australia, New Zealand
25/06	CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex Pharmaceuticals for Sugemalimab Across Australia and New Zealand
12/06	CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
12/06	CStone Pharmaceuticals Drug Receives Ethics Approval in Australia
12/06	CStone Announces Global Multicenter Phase I Clinical Trial of Its Pipeline 2.0 Core Candidate CS5007 Receives Ethics Approval from the Australian Human Research Ethics Committee
11/06	CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
11/06	Cstone Presents Clinical Data for Cs2009 Trispecific Antibody At Asco 2026
01/06	Cstone Pharmaceuticals Presents Updated Clinical Data for Cs2009 Trispecific Antibody At Asco 2026
01/06	ASCO 2026 \| CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
13/05	CStone Pharmaceuticals Plans Share Buyback
11/05	CStone Pharmaceuticals Initiates Nationwide Commercial Supply Of Locally Manufactured Pralsetinib Capsules
11/05	CStone Pharmaceuticals begins nationwide commercial supply of locally manufactured pralsetinib capsules
11/05	CStone Pharmaceuticals Begins Commercial Distribution of Locally Manufactured Pralsetinib